ERBB2 and breast carcinoma: Only one study and one study protocol reported some information on the molecular subtypes of breast cancer: the study from Zachariae [37] included 80% of patients with luminal tumors, and the protocol from Carlson [41] will include all subtypes except for HER2+ disease.